Expert consensus on medication therapy for acid-related diseases

Abstract

Acid-related diseases (ARDs) are characterized by high incidence rates and significant disease burden. Excessive gastric acid secretion or heightened gastric acid sensitivity is the common pathogenesis of these conditions, leading to the widespread application of the principle of "treating different diseases with the same therapy" in medication management. With increasing concerns about the risks of inappropriate use of acid-suppressing drugs like proton pump inhibitors (PPIs), there is an urgent need to deepen the systematic understanding of medication therapy for acid-related diseases and to promote rational drug use. This consensus was developed by a multidisciplinary panel of experts in clinical medicine, pharmacy, and methodology. Based on evidence-based medicine, it provides a systematic elaboration on the classification of ARDs, therapeutic drugs, diagnostic methods, and pharmaceutical care services. Additionally, it offers consensus-based recommendations and management strategies for key clinical issues encountered in practice. The release of this consensus is of great significance for establishing a medication therapy management system and promoting rational drug use for acid-related diseases.

Keywords

Acid-related diseases / Medication therapy / Rational drug use / Expert consensus

Declarations

Not applicable.

CRediT authorship contribution statement

Not applicable.

CRediT authorship contribution statement

Youhong Hu: Supervision.

Ethics approval and consent to participate

Not applicable.

Consent for publication

All authors have read and agreed to the published version of the manuscript and give their consent for publication in this journal.

Funding

General Program of the 2024 Scientific Research Project on Post-marketing Clinical Studies of Innovative Drugs, Center for Medical and Pharmaceutical Technology Development, National Health Commission of the PRC Grant Number: WKZX2024CX501221 Principal Investigator: Youhong Hu.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

Not applicable.

Authors' other information

Not applicable.

References

[1] FAN Xm. Acid-related diseases. Fudan University Press; 2011.

[2] Eusebi LH, Cirota GG, Zagari RM, et al. Global prevalence of barrett's oesophagus and oesophageal cancer in individuals with gastro-oesophageal reflux: a systematic review and meta-analysis. Gut. 2021; 70(3):456-463. https://doi.org/10.1136/gutjnl-2020-321365

[3] Pasricha PJ, Talley NJ. Functional dyspepsia. N Engl J Med. 2026; 394(2):166-176. https://doi.org/10.1056/NEJMcp2501860

[4] Lanas A, Chan F. Peptic ulcer disease. Lancet. 2017; 390(10094):613-624. https://doi.org/10.1016/S0140-6736(16)32404-7

[5] Yang H, Zhang M, Li H, et al. Prevalence of common upper gastrointestinal diseases in Chinese adults aged 18-64 years. Sci Bull (Beijing). 2024; 69(24):3889-3898. https://doi.org/10.1016/j.scib.2024.07.048

[6] Long Y, Xu W, Li L, et al. Characteristics and risk factors of functional dyspepsia fulfilling the rome iv criteria overlapping with gastroesophageal reflux disease, irritable bowel syndrome, and functional constipation in south China. J Neurogastroenterol Motil. 2024; 30(2):184-193. https://doi.org/10.5056/jnm23084

[7] Xiao YL, Zhou LY, Hou XH, et al. Chinese expert consensus on gastroesophageal reflux disease in 2020. J Dig Dis. 2021; 22(7):376-389. https://doi.org/10.1111/1751-2980.13028

[8] Simadibrata DM, Syam AF, Lee YY. A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2022; 37(12):2217-2228. https://doi.org/10.1111/jgh.16017

[9] Inatomi N, Matsukawa J, Sakurai Y, et al. Potassium-competitive acid blockers: advanced therapeutic option for acid-related diseases. Pharm Ther. 2016; 168:12-22. https://doi.org/10.1016/j.pharmthera.2016.08.001

[10] Veettil SK, Sadoyu S, Bald EM, et al. Association of proton-pump inhibitor use with adverse health outcomes: a systematic umbrella review of meta-analyses of cohort studies and randomised controlled trials. Br J Clin Pharm. 2022; 88(4):1551-1566. https://doi.org/10.1111/bcp.15103

[11] Chaudhry M, Elahi M, Bukhari SHA, et al. Long-term proton pump inhibitor use and the risk of kidney disease, dementia, and fractures: a systematic review. 2025; 17(8):e90627. https://doi.org/10.7759/cureus.90627

[12] Yadlapati R, Gyawali CP, Pandolfino JE. AGA clinical practice update on the personalized approach to the evaluation and management of GERD: expert review. Clin Gastroenterol Hepatol. 2022; 20(5):984-994. https://doi.org/10.1016/j.cgh.2022.01.025

[13] Wei T, Du SF, Liu B, et al. Guidelines/consensus and systematic review/meta-analysis reevaluation of proton pump inhibitors in the prevention of drug-induced gastrointestinal injury. China Pharm. 2021; 32(17) https://doi.org/10.6039/j.issn.1001-0408.2021.17.13

[14] Kang C. Keverprazan hydrochloride: first approval. Drugs. 2023; 83(7):639-643. https://doi.org/10.1007/s40265-023-01865-w

[15] Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ (Clin Res Ed ). 2017;358:j4008. https://doi.org/10.1136/bmj.j4008

[16] Higgins JPT, Altman DG, Gøtzsche PC, et al. The cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ (Clin Res Ed ). 2011;343:d5928. https://doi.org/10.1136/bmj.d5928

[17] Stang A. Critical evaluation of the newcastle-ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9):603-605. https://doi.org/10.1007/s10654-010-9491-z

[18] Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clin Res Ed ). 2008; 336(7650):924-926. https://doi.org/10.1136/bmj.39489.470347.AD

[19] Chen Y, Yang K, Marušić A, et al. A reporting tool for practice guidelines in health care: the RIGHT statement. Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen. 2017;127-128:3-10. https://doi.org/10.1016/j.zefq.2017.10.008

[20] Douglas ADrossman, Liu C, William C, et al. Functional gastrointestinal disorders disorders of gut-brain interaction. Science Press; 2016.

[21] Chinese Society Of Gastroenterology Gastrointestinal Motility Group. Greater China gastrointestinal motility alliance. Clinical guideline for esophageal ambulatory reflux monitoring in adults. Chin J Dig. 2021; 41(3) https://doi.org/10.3760/cma.j.cn311367-20210114-00032

[22] Gastroesophageal Reflux Disease Professional Committee of Digestive Physician Branch, Chinese Medical Doctor Association. Chinese guideline for high resolution esophageal manometry in clinical practice. Chin J Dig. 2020; 40(1) https://doi.org/10.3760/cma.j.issn.0254-1432.2020.01.002

[23] Pluchart H, Bailly S, Chanoine S, et al. Impact of polypharmacy and comorbidity on survival and systemic parenteral treatment administration in a cohort of hospitalized lung-cancer patients. BMC Cancer. 2023; 23(1):585. https://doi.org/10.1186/s12885-023-10939-7

[24] Liang SH, Meng HY, Kong K, et al. Propacetamol-related postoperative liver enzyme abnormalities: insights from a clinical prediction nomogram study. J Chin Pharm Sci. 2025; 34(4) https://doi.org/10.5246/jcps.2025.04.025

[25] Common terminology criteria for adverse events (CTCAE) | protocol development | CTEP[EB/OL]. ( 2017-7-1)[2025-8-18]. 〈https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm〉.

[26] The Official Website Of The National Health Commission Of The People’s Republic Of China. Excerpt from the guidelines for weight management (2024 edition). N Med. 2025; 56(6) https://doi.org/10.12464/j.issn.0253-9802.2025-0165

[27] General office of the national health commission. Notice of the general office of the national health commission on issuing the service specifications for pharmacy outpatient services and other five standards in medical institutions[EB/OL]. ( 2024-12-5)[2025-8-18]. 〈https://www.nhc.gov.cn/ylyjs/zcwj/202412/75cb79c171c94def9e768193e65484f7.shtml〉.

[28] Hammer J, Schmidt B. Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthrough. Aliment Pharm Ther. 2004; 19(10):1105-1110. https://doi.org/10.1111/j.1365-2036.2004.01949.x

[29] Tutuian R, Castell DO. Nocturnal acid breakthrough - approach to management. MedGenMed. 2004; 6(4):11.

[30] Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology. 1998; 115(6):1335-1339. https://doi.org/10.1016/s0016-5085(98)70010-1

[31] Katz PO, Anderson C, Khoury R, et al. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharm Ther. 1998; 12(12):1231-1234. https://doi.org/10.1046/j.1365-2036.1998.00419.x

[32] Katz PO, Dunbar KB, Schnoll-Sussman FH, et al. ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2022; 117(1):27-56. https://doi.org/10.14309/ajg.0000000000001538

[33] Pan T, Wang Y, Guo Z, et al. Additional bedtime h2-receptor antagonist for the control of nocturnal gastric acid breakthrough. Cochrane Database Syst Rev. 2004(4): CD004275. https://doi.org/10.1002/14651858.CD004275.pub2

[34] Katz PO, Koch FK, Ballard ED, et al. Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms. Aliment Pharm Ther. 2007; 25(2):197-205. https://doi.org/10.1111/j.1365-2036.2006.03191.x

[35] Yang E, Kim S, Kim B, et al. Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole. Br J Clin Pharm. 2022; 88(7):3288-3296. https://doi.org/10.1111/bcp.15268

[36] Zhou S, Xie L, Zhou C, et al. Keverprazan, a novel potassium-competitive acid blocker: single ascending dose safety, tolerability, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Eur J Pharm Sci. 2023; 190:106578. https://doi.org/10.1016/j.ejps.2023.106578

[37] Zou S, Ouyang M, Cheng Q, et al. Acid-suppressive drugs: a systematic review and network meta-analysis of their nocturnal acid-inhibitory effect. Pharmacotherapy. 2024; 44(2):171-183. https://doi.org/10.1002/phar.2899

[38] Wang Y, Dai X, Zhang X. Network meta-analysis of comparing different dosages of potassium-competitive acid blocker with proton-pump inhibitor in acid-related disorders. Clin Transl Gastroenterol. 2024; 15(11):e00776. https://doi.org/10.14309/ctg.0000000000000776

[39] Dong Y, Xu H, Zhang Z, et al. Comparative efficiency and safety of potassium competitive acid blockers versus lansoprazole in peptic ulcer: a systematic review and meta-analysis. Front Pharm. 2023; 14:1304552. https://doi.org/10.3389/fphar.2023.1304552

[40] Ishida M, Tsuchiya M, Naito J, et al. Vonoprazan-associated nephrotoxicity: extensive real-world evidence from spontaneous adverse drug reaction reports. Kidney Int. 2022; 102(3):666-668. https://doi.org/10.1016/j.kint.2022.06.007

[41] Hwang S, Ko JW, Lee H, et al. Co-administration of vonoprazan, not tegoprazan, affects the pharmacokinetics of atorvastatin in healthy male subjects. Front Pharm. 2021; 12:754849. https://doi.org/10.3389/fphar.2021.754849

[42] Jankovic K, Gralnek IM, Awadie H. Emerging long-term risks of the use of proton pump inhibitors and potassium-competitive acid blockers. Annu Rev Med. 2025; 76(1):143-153. https://doi.org/10.1146/annurev-med-050223-112834

[43] Kushima R, Uemura N, Kinoshita Y, et al. Ep1118: 4-year interim analysis results of vision trial: a randomized, open-label study to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive esophagitis. Gastroenterology. 2022; 162(7, ement):1066--1067. https://doi.org/10.1016/S0016-5085(22)62550-2

[44] Aiba M, Tsutsumi Y, Nagai J, et al. Convulsive seizure due to hypomagnesemia caused by short-term vonoprazan intake. Intern Med. 2022; 61(2):237-240. https://doi.org/10.2169/internalmedicine.7758-21

[45] Okamoto M, Wakunami Y, Hashimoto K. Severe hypomagnesemia associated with the long-term use of the potassium-competitive acid blocker vonoprazan. Intern Med. 2022; 61(1):119-122. https://doi.org/10.2169/internalmedicine.7325-21

[46] Moayyedi P, Lacy BE, Andrews CN, et al. ACG and CAG clinical guideline: management of dyspepsia. Am J Gastroenterol. 2017; 112(7):988-1013. https://doi.org/10.1038/ajg.2017.154

[47] Miwa H, Nagahara A, Asakawa A, et al. Evidence-based clinical practice guidelines for functional dyspepsia 2021. J Gastroenterol. 2022; 57(2):47-61. https://doi.org/10.1007/s00535-021-01843-7

[48] Ford AC, Moayyedi P, Black CJ, et al. Systematic review and network meta-analysis: efficacy of drugs for functional dyspepsia. Aliment Pharm Ther. 2021; 53(1):8-21. https://doi.org/10.1111/apt.16072

[49] Zhou W, Li X, Huang Y, et al. Comparative efficacy and acceptability of psychotropic drugs for functional dyspepsia in adults: a systematic review and network meta-analysis. Med (Baltim). 2021; 100(20):e26046. https://doi.org/10.1097/MD.0000000000026046

[50] Talley NJ, Locke GR, Saito YA, et al. Effect of amitriptyline and escitalopram on functional dyspepsia: a multicenter, randomized controlled study. Gastroenterology. 2015; 149(2):340-349. https://doi.org/10.1053/j.gastro.2015.04.020

[51] Luo L, Du L, Shen J, et al. Benefit of small dose antidepressants for functional dyspepsia: experience from a tertiary center in eastern china. Med (Baltim). 2019; 98(41):e17501. https://doi.org/10.1097/MD.0000000000017501

[52] Chen MH, Fang XC, Hou XH, et al. 2022 chinese expert consensus on the diagnosis and treatment of functional dyspepsia (FD). Gastroenterology. 2023; 28(08):467-481.

[53] Savarino EV, Barberio B, Scarpignato C, et al. Italian guidelines for the diagnosis and management of gastro-esophageal reflux disease: joint consensus from the italian societies of: gastroenterology and endoscopy (SIGE), neurogastroenterology and motility (SINGEM), hospital gastroenterologists and endoscopists (AIGO), digestive endoscopy (SIED), and general medicine (SIMG). Dig Liver Dis. 2025; 57(8):1550-1577. https://doi.org/10.1016/j.dld.2025.04.020

[54] Si XB, Huo LY, Bi DY, et al. Comparative efficacy of antidepressants for symptoms remission of gastroesophageal reflux: a bayesian network meta-analysis of randomized controlled trials. Turk J Gastroenterol. 2021; 32(10):843-853. https://doi.org/10.5152/tjg.2021.20607

[55] Yeh JH, Chen CL, Sifrim D, et al. Central neuromodulators for patients with functional esophageal disorders: a systematic review and meta-analysis. Dig Liver Dis. 2024; 56(10):1675-1682. https://doi.org/10.1016/j.dld.2024.05.013

[56] Viazis N, Keyoglou A, Kanellopoulos AK, et al. Selective serotonin reuptake inhibitors for the treatment of hypersensitive esophagus: a randomized, double-blind, placebo-controlled study. Am J Gastroenterol. 2012; 107(11):1662-1667. https://doi.org/10.1038/ajg.2011.179

[57] Yamasaki T, Fass R. Reflux hypersensitivity: a new functional esophageal disorder. J Neurogastroenterol Motil. 2017; 23(4):495-503. https://doi.org/10.5056/jnm17097

[58] Digestive System Diseases Professional Committee. Chinese association of integrative medicine. Expert consensus on integrated traditional chinese and western medicine diagnosis and treatment of gastroesophageal reflux disease(2025). Chin J Integr Tradit West Med Dig. 2025; 33(03):217-229.

[59] Chen MH, Li YQ, Xiao YL, et al. Chinese guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Gastroenterology. 2023; 28(10):597-607.

[60] Reid M, Keniston A, Heller JC, et al. Inappropriate prescribing of proton pump inhibitors in hospitalized patients. J Hosp Med. 2012; 7(5):421-425. https://doi.org/10.1002/jhm.1901

[61] Savarino V, Marabotto E, Zentilin P, et al. Proton pump inhibitors: use and misuse in the clinical setting. Expert Rev Clin Pharm. 2018; 11(11):1123-1134. https://doi.org/10.1080/17512433.2018.1531703

[62] Sattayalertyanyong O, Thitilertdecha P, Auesomwang C. The inappropriate use of proton pump inhibitors during admission and after discharge: a prospective cross-sectional study. Int J Clin Pharm. 2020; 42(1):174-183. https://doi.org/10.1007/s11096-019-00955-8

[63] Alhazzani W, Guyatt G, Alshahrani M, et al. Withholding pantoprazole for stress ulcer prophylaxis in critically ill patients: a pilot randomized clinical trial and meta-analysis. Crit Care Med. 2017; 45(7):1121-1129. https://doi.org/10.1097/CCM.0000000000002461

[64] Kwok CS, Arthur AK, Anibueze CI, et al. Risk of clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol. 2012; 107(7):1011-1019. https://doi.org/10.1038/ajg.2012.108

[65] Poly TN, Islam MM, Yang HC, et al. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies. Osteoporos Int. 2019; 30(1):103-114. https://doi.org/10.1007/s00198-018-4788-y

[66] Dial S, Alrasadi K, Manoukian C, et al. Risk of clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ. 2004; 171(1):33-38. https://doi.org/10.1503/cmaj.1040876

[67] Buendgens L, Koch A, Tacke F. Prevention of stress-related ulcer bleeding at the intensive care unit: risks and benefits of stress ulcer prophylaxis. World J Crit Care Med. 2016; 5(1):57-64. https://doi.org/10.5492/wjccm.v5.i1.57

[68] Emergency Physician Branch Of Chinese Medical Doctor Association. Chinese expert consensus on acute gastric mucosal lesion in emergency medicine. Chin J Emerg Med. 2015; 24(10) https://doi.org/10.3760/cma.j.issn.1671-0282.2015.10.004

[69] Bai Y, Li YQ, Ren X, et al. Expert recommendations for the prevention and treatment of stress ulcers (2015 edition). Natl Med J China. 2015; 95(20) https://doi.org/10.3760/cma.j.issn.0376-2491.2015.20.002

[70] Chinese Society Of Surgery. Chinese medical association. Prevention and treatment of stress-related mucosal disease: chinese general surgery expert consensus (2015). Chin J Pract Surg. 2015; 35(7) https://doi.org/10.7504/CJPS.ISSN1005-2208.2015.07.10

[71] Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009; 104(3):728-738. https://doi.org/10.1038/ajg.2009.115

[72] Shalev A, Zahger D, Novack V, et al. Incidence, predictors and outcome of upper gastrointestinal bleeding in patients with acute coronary syndromes. Int J Cardiol. 2012; 157(3):386-390. https://doi.org/10.1016/j.ijcard.2010.12.081

[73] Hallas J, Dall M, Andries A, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ. 2006; 333(7571):726. https://doi.org/10.1136/bmj.38947.697558.AE

[74] Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut. 2006; 55(12):1731-1738. https://doi.org/10.1136/gut.2005.080754

[75] Garcia RL, Lin KJ, Hernandez-Diaz S, et al. Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. Circulation. 2011; 123(10):1108-1115. https://doi.org/10.1161/CIRCULATIONAHA.110.973008

[76] Yeomans ND, Lanas AI, Talley NJ, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharm Ther. 2005; 22(9):795-801. https://doi.org/10.1111/j.1365-2036.2005.02649.x

[77] Jensen BE, Hansen JM, Junker AB, et al. High prevalence of ulcer bleeding risk factors in dual antiplatelet-treated patients after percutaneous coronary intervention. Dan Med J. 2015; 62(6).

[78] Taha AS, Angerson WJ, Prasad R, et al. Clinical trial: the incidence and early mortality after peptic ulcer perforation, and the use of low-dose aspirin and non-steroidal anti-inflammatory drugs. Aliment Pharm Ther. 2008; 28(7):878-885. https://doi.org/10.1111/j.1365-2036.2008.03808.x

[79] Devi DP, Sushma M, Guido S. Drug-induced upper gastrointestinal disorders requiring hospitalization: a five-year study in a south indian hospital. Pharmacoepidemiol Drug Saf. 2004; 13(12):859-862. https://doi.org/10.1002/pds.988

[80] Jung DH, Youn YH, Kim JH, et al. Factors influencing development of pain after gastric endoscopic submucosal dissection: a randomized controlled trial. Endoscopy. 2015; 47(12):1119-1123. https://doi.org/10.1055/s-0034-1392537

[81] Hospital Pharmacy Committee of the Chinese Pharmaceutical Association, Clinical Pharmacy Branch of the Chinese Medical Association, Expert Consensus Working Group on the Optimized Application of Proton Pump Inhibitors. Expert consensus on optimal application of proton pump inhibitors. Chin J Hosp Pharm. 2020; 40(21) https://doi.org/10.13286/j.1001-5213.2020.21.01

[82] Fossmark R, Martinsen TC, Waldum HL. Adverse effects of proton pump inhibitors- evidence and plausibility. Int J Mol Sci. 2019; 20(20) https://doi.org/10.3390/ijms20205203

[83] Cundy T, Dissanayake A. Severe hypomagnesaemia in long-term users of proton-pump inhibitors. Clin Endocrinol (Oxf). 2008; 69(2):338-341. https://doi.org/10.1111/j.1365-2265.2008.03194.x

[84] Lam JR, Schneider JL, Zhao W, et al. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin b12 deficiency. JAMA. 2013; 310(22):2435-2442. https://doi.org/10.1001/jama.2013.280490

[85] Xun X, Yin Q, Fu Y, et al. Proton pump inhibitors and the risk of community-acquired pneumonia: an updated meta-analysis. Ann Pharm. 2022; 56(5):524-532. https://doi.org/10.1177/10600280211039240

[86] Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016; 176(2):238-246. https://doi.org/10.1001/jamainternmed.2015.7193

[87] Helicobacter Pylori Study Group, Chinese Society of Gastroenterology, Chinese Medical Association. 2022 chinese national clinical practice guideline on helicobacter pylori eradication treatment. Chin J Gastroenterol. 2022; 27(3) https://doi.org/10.3969/j.issn.1008-7125.2022.03.004

[88] Malfertheiner P, Megraud F, Rokkas T, et al. Management of helicobacter pylori infection: the maastricht VI/florence consensus report. Gut. 2022. https://doi.org/10.1136/gutjnl-2022-327745

[89] Shah SC, Iyer PG, Moss SF. AGA clinical practice update on the management of refractory helicobacter pylori infection: expert review. Gastroenterology. 2021; 160(5):1831-1841. https://doi.org/10.1053/j.gastro.2020.11.059

[90] Nyssen OP, Perez-Aisa A, Castro-Fernandez M, et al. European registry on helicobacter pylori management: single-capsule bismuth quadruple therapy is effective in real-world clinical practice. U Eur Gastroenterol J. 2021; 9(1):38-46. https://doi.org/10.1177/2050640620972615

[91] Nyssen OP, Mcnicholl AG, Gisbert JP. Meta-analysis of three-in-one single capsule bismuth-containing quadruple therapy for the eradication of helicobacter pylori. Helicobacter. 2019; 24(2):e12570. https://doi.org/10.1111/hel.12570

[92] Nyssen OP, Perez-Aisa A, Rodrigo L, et al. Bismuth quadruple regimen with tetracycline or doxycycline versus three-in-one single capsule as third-line rescue therapy for helicobacter pylori infection: spanish data of the european helicobacter pylori registry (hp-EuReg). Helicobacter. 2020; 25(5):e12722. https://doi.org/10.1111/hel.12722

[93] Zullo A, De Francesco V, Bellesia A, et al. Bismuth-based quadruple therapy following h. Pylori eradication failures: a multicenter study in clinical practice. J Gastrointestin Liver Dis. 2017; 26(3):225-229. https://doi.org/10.15403/jgld.2014.1121.263.zul

[94] Delchier JC, Malfertheiner P, Thieroff-Ekerdt R. Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of helicobacter pylori. Aliment Pharm Ther. 2014; 40(2):171-177. https://doi.org/10.1111/apt.12808

[95] Muller N, Amiot A, Le Thuaut A, et al. Rescue therapy with bismuth-containing quadruple therapy in patients infected with metronidazole-resistant helicobacter pylori strains. Clin Res Hepatol Gastroenterol. 2016; 40(4):517-524. https://doi.org/10.1016/j.clinre.2015.12.012

[96] Rodriguez DSE, Martin DADP, Marcos PH, et al. Limited effectiveness with a 10-day bismuth-containing quadruple therapy (pylera((r))) in third-line recue treatment for helicobacter pylori infection. A real-life multicenter study. Helicobacter. 2017; 22(5) https://doi.org/10.1111/hel.12423

[97] Nyssen OP, Perez-Aisa A, Tepes B, et al. Helicobacter pylori first-line and rescue treatments in patients allergic to penicillin: experience from the european registry on h pylori management (hp-EuReg). Helicobacter. 2020; 25(3):e12686. https://doi.org/10.1111/hel.12686

[98] Zhou JJ, Shi X, Zheng SP, et al. Efficacy of bismuth-based quadruple therapy for eradication of helicobacter pylori infection based on previous antibiotic exposure: a large-scale prospective, single-center clinical trial in china. Helicobacter. 2020; 25(6):e12755. https://doi.org/10.1111/hel.12755

[99] Mori H, Suzuki H, Matsuzaki J, et al. Acquisition of double mutation in gyra caused high resistance to sitafloxacin in helicobacter pylori after unsuccessful eradication with sitafloxacin-containing regimens. U Eur Gastroenterol J. 2018; 6(3):391-397. https://doi.org/10.1177/2050640617737215

[100] Mori H, Suzuki H, Matsuzaki J, et al. 10-year trends in helicobacter pylori eradication rates by sitafloxacin-based third-line rescue therapy. Digestion. 2020; 101(5):644-650. https://doi.org/10.1159/000501610

[101] Gatta L, Zullo A, Perna F, et al. A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. Aliment Pharm Ther. 2005; 22(1):45-49. https://doi.org/10.1111/j.1365-2036.2005.02522.x

[102] Gisbert JP. Empirical or susceptibility-guided treatment for helicobacter pylori infection? A comprehensive review. Ther Adv Gastroenterol. 2020; 13:1756284820968736. https://doi.org/10.1177/1756284820968736

[103] Savoldi A, Carrara E, Graham DY, et al. Prevalence of antibiotic resistance in helicobacter pylori: a systematic review and meta-analysis in world health organization regions. Gastroenterology. 2018; 155(5):1372-1382. https://doi.org/10.1053/j.gastro.2018.07.007

[104] Huang Y, Chen J, Ding Z, et al. Minocycline vs. Tetracycline in bismuth-containing quadruple therapy for helicobacter pylori rescue treatment: a multicentre, randomized controlled trial. J Gastroenterol. 2023; 58(7):633-641. https://doi.org/10.1007/s00535-023-01991-y

[105] Tanabe H, Yoshino K, Ando K, et al. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for helicobacter pylori eradication. Ann Clin Microbiol Antimicrob. 2018; 17(1):29. https://doi.org/10.1186/s12941-018-0281-x

[106] Murakami K, Sakurai Y, Shiino M, et al. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016; 65(9):1439-1446. https://doi.org/10.1136/gutjnl-2015-311304

[107] Furuta T, Yamade M, Kagami T, et al. Dual therapy with vonoprazan and amoxicillin is as effective as triple therapy with vonoprazan, amoxicillin and clarithromycin for eradication of helicobacter pylori. Digestion. 2020; 101(6):743-751. https://doi.org/10.1159/000502287

[108] Zeng SY, Wang J, Liu J, et al. Efficacy and safety of a 14-day modified concomitant therapy for refractory helicobacter pylori infection: a pilot study. J Gastroenterol Hepatol. 2023; 38(12):2097-2103. https://doi.org/10.1111/jgh.16348

[109] Sue S, Shibata W, Sasaki T, et al. Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for helicobacter pylori. J Gastroenterol Hepatol. 2019; 34(4):686-692. https://doi.org/10.1111/jgh.14456

[110] National Health Commission Of The People’s Republic Of China. Clinical application guidelines for proton pump inhibitors (2020 edition). Chin Pract J Rural Dr. 2021; 28(1) https://doi.org/10.3969/j.issn.1672-7185.2021.01.001

[111] Hunt R, B LL, C MY, et al. International consensus on guiding recommendations for management of patients with nonsteroidal antiinflammatory drugs induced gastropathy-ICON-g. Eur J Hepatogastroenterol. 2018; 8(2):148-160. https://doi.org/10.5005/jp-journals-10018-1281

[112] Rostom A, Dube C, Wells G, et al. Prevention of NSAID-induced gastroduodenal ulcers. CD 002296 Cochrane Database Syst Rev. 2002(4) https://doi.org/10.1002/14651858.CD002296

[113] Agrawal NM, Campbell DR, Safdi MA, et al. Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. NSAID-Assoc Gastric ulcer Study Group Arch Intern Med. 2000; 160(10):1455-1461. https://doi.org/10.1001/archinte.160.10.1455

[114] Chey WD, Howden CW, Moss SF, et al. ACG clinical guideline: treatment of helicobacter pylori infection. Am J Gastroenterol. 2024; 119(9):1730-1753. https://doi.org/10.14309/ajg.0000000000002968

[115] Helicobacter Pylori Study Group, Chinese Society Of Gastroenterology. The sixth national consensus report on the management of helicobacter pylori infection (non-eradication treatment section). Gastroenterology. 2022; 27(05):289-304.

[116] Hawkey C, Avery A, Coupland C, et al. Helicobacter pylori eradication for primary prevention of peptic ulcer bleeding in older patients prescribed aspirin in primary care (HEAT): a randomised, double-blind, placebo-controlled trial. Lancet. 2022; 400(10363):1597-1606. https://doi.org/10.1016/S0140-6736(22)01843-8

[117] Sarri GL, Grigg SE, Yeomans ND. Helicobacter pylori and low-dose aspirin ulcer risk: a meta-analysis. J Gastroenterol Hepatol. 2019; 34(3):517-525. https://doi.org/10.1111/jgh.14539

[118] Zhang X, Xiao X, Chen PR, et al. Proton pump inhibitors increase the risk of non-steroidal anti-inflammatory drug-related small-bowel injury: a systematic review with meta-analysis. Clin Transl Gastroenterol. 2023; 14(6):e00588. https://doi.org/10.14309/ctg.0000000000000588

[119] Washio E, Esaki M, Maehata Y, et al. Proton pump inhibitors increase incidence of nonsteroidal anti-inflammatory drug-induced small bowel injury: a randomized, placebo-controlled trial. Clin Gastroenterol Hepatol. 2016; 14(6):809-815. https://doi.org/10.1016/j.cgh.2015.10.022

[120] Nadatani Y, Watanabe T, Suda W, et al. Gastric acid inhibitor aggravates indomethacin-induced small intestinal injury via reducing lactobacillus johnsonii. Sci Rep. 2019; 9(1):17490. https://doi.org/10.1038/s41598-019-53559-7

[121] Wallace JL, Syer S, Denou E, et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. 1321-1322 Gastroenterology. 2011; 141(4):1314-1322. https://doi.org/10.1053/j.gastro.2011.06.075

[122] Xiong L, Huang X, Li L, et al. Geranylgeranylacetone protects against small-intestinal injuries induced by diclofenac in patients with rheumatic diseases: a prospective randomized study. Dig Liver Dis. 2015; 47(4):280-284. https://doi.org/10.1016/j.dld.2015.01.005

[123] Niwa Y, Nakamura M, Miyahara R, et al. Geranylgeranylacetone protects against diclofenac-induced gastric and small intestinal mucosal injuries in healthy subjects: a prospective randomized placebo-controlled double-blind cross-over study. Digestion. 2009; 80(4):260-266. https://doi.org/10.1159/000236032

[124] Nakada K, Hanyu N, Mitsumori N, et al. [ The usefulness of prokinetics in the treatment of acid-related disease]. Nihon Rinsho. 2015; 73(7):1175-1178.

[125] Xu L. Interpretation of the chinese expert consensus on gastroesophageal reflux disease in the elderly (2023). Gerontol Health Care. 2023; 29(05):876-879.

[126] Chinese Society Of Gastroenterology,Chinese Medical Association. Chinese expert consensus of gastroesophageal reflux disease in 2020. Chin J Dig. 2020; 40(10) https://doi.org/10.3760/cma.j.cn311367-20200918-00558

[127] Maneerattanaporn M, Pittayanon R, Patcharatrakul T, et al. Thailand guideline 2020 for medical management of gastroesophageal reflux disease. J Gastroenterol Hepatol. 2022; 37(4):632-643. https://doi.org/10.1111/jgh.15758

[128] Iwakiri K, Fujiwara Y, Manabe N, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021. J Gastroenterol. 2022; 57(4):267-285. https://doi.org/10.1007/s00535-022-01861-z

[129] Bor S, Kalkan IH, Savarino E, et al. Prokinetics-safety and efficacy: the european society of neurogastroenterology and motility/the american neurogastroenterology and motility society expert review. Neurogastroenterol Motil. 2024; 36(5):e14774. https://doi.org/10.1111/nmo.14774

[130] Xi L, Zhu J, Zhang H, et al. The treatment efficacy of adding prokinetics to PPIs for gastroesophageal reflux disease: a meta-analysis. Esophagus. 2021; 18(1):144-151. https://doi.org/10.1007/s10388-020-00753-6

[131] Jung DH, Huh CW, Lee SK, et al. A systematic review and meta-analysis of randomized control trials: combination treatment with proton pump inhibitor plus prokinetic for gastroesophageal reflux disease. J Neurogastroenterol Motil. 2021; 27(2):165-175. https://doi.org/10.5056/jnm20161

[132] Ren LH, Chen WX, Qian LJ, et al. Addition of prokinetics to PPI therapy in gastroesophageal reflux disease: a meta-analysis. World J Gastroenterol. 2014; 20(9):2412-2419. https://doi.org/10.3748/wjg.v20.i9.2412

[133] Zamani NF, Sjahid AS, Tuan KT, et al. Efficacy and safety of domperidone in combination with proton pump inhibitors in gastroesophageal reflux disease: a systematic review and meta-analysis of randomised controlled trials. J Clin Med. 2022; 11(18) https://doi.org/10.3390/jcm11185268

[134] Lima JJ, Thomas CD, Barbarino J, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2c19 and proton pump inhibitor dosing. Clin Pharm Ther. 2021; 109(6):1417-1423. https://doi.org/10.1002/cpt.2015

[135] Chevalier R, Attard T, Van Driest SL, et al. A fresh look at proton pump inhibitor (PPI)-associated adverse events through a CYP2c19 pharmacogenetic lens. Expert Opin Drug Metab Toxicol. 2023; 19(2):53-56. https://doi.org/10.1080/17425255.2023.2190883

[136] Shah SC, Tepler A, Chung CP, et al. Host genetic determinants associated with helicobacter pylori eradication treatment failure: a systematic review and meta-analysis. Gastroenterology. 2021; 161(5):1443-1459. https://doi.org/10.1053/j.gastro.2021.07.043

[137] Biswas M, Rahaman S, Biswas TK, et al. Risk of major adverse cardiovascular events for concomitant use of clopidogrel and proton pump inhibitors in patients inheriting CYP2c19 loss-of-function alleles: meta-analysis. Int J Clin Pharm. 2021; 43(5):1360-1369. https://doi.org/10.1007/s11096-021-01261-y

[138] Abouir K, Exquis N, Gloor Y, et al. Phenoconversion due to drug-drug interactions in CYP2c19 genotyped healthy volunteers. Clin Pharm Ther. 2024; 116(4):1121-1129. https://doi.org/10.1002/cpt.3378

[139] Rohr BS, Krohmer E, Foerster KI, et al. Time course of the interaction between oral short-term ritonavir therapy with three factor xa inhibitors and the activity of CYP2d6, CYP2c19, and CYP3a4 in healthy volunteers. Clin Pharm. 2024; 63(4):469-481. https://doi.org/10.1007/s40262-024-01350-x

[140] Mougey EB, Williams A, Coyne A, et al. CYP2c19 and STAT6 variants influence the outcome of proton pump inhibitor therapy in pediatric eosinophilic esophagitis. J Pedia Gastroenterol Nutr. 2019; 69(5):581-587. https://doi.org/10.1097/MPG.0000000000002480

[141] Ichikawa H, Sugimoto M, Sugimoto K, et al. Rapid metabolizer genotype of CYP2c19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis. J Gastroenterol Hepatol. 2016; 31(4):716-726. https://doi.org/10.1111/jgh.13233

[142] Wada F, Murase K, Isomoto H, et al. Polymorphism of CYP2c19 and gastric emptying in patients with proton pump inhibitor-resistant gastric ulcers. J Int Med Res. 2002; 30(4):413-421. https://doi.org/10.1177/147323000203000408

[143] Smolle KH, Kullnig P, Logar C, et al. [Clinical assessment and therapy of barbiturate poisoning (based on 2 case reports)]. Wien Klin Woche. 1987; 99(22):793-798.